Business Context and Reporting Period
This Form 8-K Current Report was filed by Chewy, Inc. on April 24, 2025. The filing addresses a corporate governance event involving the expansion of the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the appointment of a new director and does not contain financial performance data.
Material Changes
The Board of Directors increased its size from thirteen to fourteen members. Dr. Nat Goldhaber was appointed as a Class I director to fill the newly created vacancy. His term is set to expire at the Company's annual meeting of stockholders in 2026. The Board determined that Dr. Goldhaber is independent under SEC and NYSE rules.
Outlook, Risks, and Management Commentary
Dr. Goldhaber brings extensive experience in venture capital, technology, and public service. He currently serves as Managing Director of Claremont Creek Ventures, a firm specializing in clean energy and healthcare. His background includes founding CyberGold, Inc., serving as President of Kaleida Labs, and holding public office in Pennsylvania. He is eligible to receive standard annual compensation for non-affiliated directors and has entered into an indemnification agreement with the Company. No other transactions requiring disclosure under Item 404(a) of Regulation S-K were identified.
Key Facts for Investor Verification
- Dr. Nat Goldhaber's appointment as an independent Class I director effective April 24, 2025.
- The Board size increase from 13 to 14 directors.
- Dr. Goldhaber's term expiration at the 2026 annual meeting of stockholders.
- Confirmation of standard director compensation and indemnification terms.